A large pharmaceutical company was approached to license a drug being developed to treat diabetic nephropathy. The company had less than two weeks to assess the business opportunity and determine if it was a venture in which they wanted to invest. To make that decision, the company wanted to know more about the marketplace for drugs in this therapeutic category and, specifically, if there were unmet needs that this new drug would address.
Is the market viable enough to warrant a "yes" decision on the in-licensing opportunity?
To answer this question, Answers & Insights went to those most qualified to answer it: the physicians who treat patients with diabetic nephropathy. Using its proprietary database of more than 500,000 physicians, Answers & Insights identified physicians across the U.S. who commonly treat patients with diabetic nephropathy.
Answers & Insights scheduled IDIs, or in-depth interviews, with 30 physicians. Using web conferencing, an experienced Answers & Insights moderator – one with extensive health care experience and knowledge on this specific therapeutic category – conducted interviews to gather qualitative information on:
Additionally, during the IDIs, each physician reviewed a profile of the proposed licensing product and provided input on:
With an already established understanding of the therapeutic category, as well as the ability to quickly identify and secure a sampling of physicians, Answers & Insights was able to recruit respondents, design and execute a research plan, and deliver a project report—and all within the short time needed. With the information in hand, the pharmaceutical company was able to confidently make a decision that was based on a sampling of qualitative data from experienced physicians.